Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | GNRHR | P30968 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912948 | 1.00 | UBE2N (0.47) | UBE2NTDP1SLC1A1CA2CA9 | |
| SCHEMBL676621 | 1.00 | UBE2N (0.47) | UBE2NTDP1SLC1A1CA2CA9 | |
| SCHEMBL29559650 | 1.00 | UBE2N (0.47) | UBE2NTDP1SLC1A1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL1530005 | 0.99 | UBE2N (0.46) | UBE2NTDP1SLC1A1CA2CA9 | |
| Trifluoroacetic Acid SCHEMBL10323420 | 0.91 | GNRHR (0.48) | UBE2NTDP1SLC1A1GNRHRDPP4 | |
| SCHEMBL4583448 | 0.89 | CASP3 (0.46) | UBE2NTDP1GNRHRCASP3ALDH1A1 | |
| SCHEMBL1530021 | 0.89 | CASP3 (0.46) | UBE2NTDP1GNRHRCASP3ALDH1A1 | |
| SCHEMBL30890110 | 0.89 | CASP3 (0.46) | UBE2NTDP1GNRHRCASP3ALDH1A1 | |
| SCHEMBL1530019 | 0.89 | CASP3 (0.46) | UBE2NTDP1GNRHRCASP3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1529443 | 0.87 | CASP3 (0.44) | UBE2NTDP1GNRHRCASP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2117523-B1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2009158376-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158372-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158374-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158371-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLIKE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158373-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2117523-A1 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008098104-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | UBE2N 1357/4885TDP1 657/4885SLC1A1 3019/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | UBE2N 2419/4885TDP1 969/4885SLC1A1 3425/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | UBE2N 2419/4885TDP1 969/4885SLC1A1 3425/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | UBE2N 2419/4885TDP1 969/4885SLC1A1 3425/4885 |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | UBE2N 2419/4885TDP1 969/4885SLC1A1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.